Cipla Ltd.

Cipla has informed that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection at its API manufacturing facility in Virgonangar, Bengaluru, from 15th June, 2019 to 19th June, 2019. The inspection ended with 7 observations, none of which were repeat or related to data integrity. The Company will respond to the agency within the stipulated timeline.

The above information is a part of company’s filings submitted to BSE.